Subscribe To
AFMD / Affimed N.V. (AFMD) Q3 2022 Earnings Call Transcript
AFMD News
By GlobeNewsWire
November 1, 2023
Affimed to Participate in Upcoming Investor Conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolog more_horizontal
By Zacks Investment Research
October 25, 2023
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal
By GlobeNewsWire
September 21, 2023
Affimed to Present at the Cantor Global Healthcare Conference 2023
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncol more_horizontal
By GlobeNewsWire
September 7, 2023
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving pati more_horizontal
By InvestorPlace
August 23, 2023
Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.
Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, more_horizontal
By Zacks Investment Research
August 10, 2023
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. more_horizontal
By InvestorPlace
August 4, 2023
3 Cheap Stocks to Buy Under $1 in August 2023
The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent. more_horizontal
By GlobeNewsWire
August 3, 2023
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patie more_horizontal